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Sick Sinus Syndrome After a Single Oral
Administration of Garenoxacin
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The Department of Cardiology, Matsunami General Hospital
This report presents the case of a 60-year-old female who demonstrated sick sinus
syndrome after a single administration of Garenoxacin (GRNX). She was administered
GRNX for an upper respiratory infection and 10 minutes thereafter, she suddenly felt
palpitation and numbness of both arms. She was transferred to the hospital 2 hours after taking
GRNX. An electrocardiogram showed bradycardia with junctional escape beats and the
longest sinus arrest was 4 seconds. She was treated with a temporary pacemaker and 21 hours
after the administration of GRNX her sinus node function was observed to have completely
improved. GRNX-induced sick sinus syndrome was suspected because her clinical course was
compatible with the concentration of GRNX and her other cardiological assessments,
including an electrophysiologic study (EPS) which were conducted on the 9th day of the
admission, were normal. GRNX has less eﬀect on the QT interval than other quinolone
agents. However, physicians should be aware of the risk of sick sinus syndrome because
GRNX is frequently prescribed in outpatient clinics.
(J Arrhythmia 2010; 26: 62–66)
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Introduction
Garenoxacin mesilate hydrate (GRNX), a novel
des-ﬂuoro(6)-quinolone antibacterial agent, was
marketed in Japan in October 2007. It is eﬀective
against a wide range of pathogens with good
intestinal absorption and tissue distribution.1) Al-
though quinolone has known cardiac side eﬀects,
especially QT prolongation and torsades de pointes,2)
sick sinus syndrome (SSS) associated with quinolone
is extremely rare. GRNX has less eﬀect on the QT
interval than other quinolone agents and is consid-
ered to be a safe drug.3) However, a recent patient
experienced SSS caused by a single dose of GRNX.
New oral quinolone antibacterial agents are gain-
ing in popularity, especially for treatment of respi-
ratory infection. However, physicians should be
aware of the possibility of SSS in normal subjects
even with a single dose of GRNX because it is
frequently prescribed in outpatient clinics.
Case report
A 60-year-old Japanese female was transferred to
the hospital because of palpitations, numbness of
both arms and faintness. She had no history of any
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Case Report
serious illness before and had never experienced
such symptoms previously. An electrocardiogram
(ECG) taken 1 year earlier for a medical check was
normal. She was diagnosed with an upper respiratory
infection at a nearby hospital and was prescribed
carbocisteine (750mg/day, 3 times per day) and
GRNX (400mg/day, once per day). She had taken
carbocisteine at noon and GRNX in the evening.
Ten minutes after the intake of GRNX, she felt
palpitation and numbness of both arms. Although
she rested, the palpitations did not improve and
she then began to feel faint. She was transferred to
this hospital 2 hours after taking GRNX. The
ECGs which were taken in the ambulance and
the emergency room showed bradycardia, 40 to
60 beats/min with junctional escape beats as dem-
onstrated in Figure 1.
On arrival, she was alert and complained of only
palpitation. Her height was 152.0 cm and weight was
50.0 kg. Her body temperature was 36.5 C and
blood pressure was 98/35mmHg. (Her usual systolic
blood pressure was around 140mmHg) There were
no other abnormalities found during the physical
examination. Thyroid hormones, renal functions and
electrolytes including potassium were within normal
limits. She was admitted and monitored continuously
by telemetry without any medication including
GRNX because no long sinus arrest or cardiac
failure were observed at that time.
A long sinus pause was observed for the ﬁrst time
8 hours after the administration of GRNX. ECG
revealed a junctional bradycardia of 30 to 40 beats/
min, occasional sinus beats, and the longest sinus
arrest was 4 seconds as shown in Figure 2. The QT
interval was not prolonged. Her blood pressure was
68/39mmHg at that time and she vomited several
times. Noradrenaline (1.7 mg/kg/hr, continuous in-
fusion) and dopamine (0.17mg/kg/hr, continuous
infusion) were administered immediately to treat her
for shock. She was diagnosed to have SSS and a
temporary transvenous pacemaker was inserted. The
pacemaker was set to the VVI mode with a lower
rate of 50 beats/min and a pacing amplitude of 3.0V
for the ventricle. The ventricular sensing threshold
was normal and no pacing failure was observed
during the insertion of the pacemaker. Her baseline
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Figure 1
ECG taken in the emergency room showed bradycardia with junctional escape beats, and a decreased heart rate with variability ranging
from 40 to 60 beats/min.
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heart rate gradually returned to normal and her
native rhythm was detectable 21 hours after the
administration of GRNX, as shown in Figure 3. The
pacemaker rate was decreased gradually, but no
sinus arrest was observed. Her electrocardiographic
time-dependent changes are summarized in Table 1.
The temporary pacemaker was removed 3 days
after insertion because her sinus node function
had suﬃciently improved. Coronary angiography
showed no abnormality and cardiac function assess-
ment by a left ventriculogram and Swan-Ganz
catheter assessment were also normal 9 days after
the admission. She also underwent an electrophysio-
logic study (EPS) and an overdrive suppression test
to determine the sinus node recovery time (SNRT).
The basic cycle length was 1000msec and the
longest period of post-pacing arrest was 1450msec,
yielding a corrected SNRT of 500msec.
The serum concentrations of GRNX were 4.39
mg/ml (2 hours after administration), 4.01 mg/ml (9
hours), 0.76 mg/ml (33 hours), and 0.19 mg/ml (57
hours), respectively. A drug lymphocyte stimulation
test for GRNX was negative.
No further episodes of SSS were observed without
the pacemaker or with any medication.
Discussion
SSS is an abnormal heart rhythm involving sinus
arrest, sinus node exit block and severe sinus
bradycardia. In addition to the intrinsic causes of
SSS, elevated potassium,4) hypothyroidism5) and
hyperthyroidism6) are reported as the extrinsic
causes of SSS. Sympatholytic medication and anti-
arrhythmic agents as well as lithium7) and carbama-
zepine7) are reported to induce drug-associated SSS.
However, SSS is very rare after the administration of
quinolone antibacterial agents.
GRNX, a novel des-ﬂuoro(6)-quinolone antibac-
terial agent is eﬀective against a wide range of
clinically important pathogens.8) It is rapidly absorb-
ed and widely distributed into the tissues of most
organs except the cerebrum and spinal cord.1)
Both the therapeutic and adverse eﬀects of GRNX
depend on its serum concentrations which increase
with increasing doses following once daily admin-
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Figure 2
Long sinus pauses were observed 8 hours after the oral administration of GRNX. This ECG revealed a junctional bradycardia of 30 to
40 beats/min with occasional sinus beats, and long periods of sinus arrest (the longest arrest was 4 seconds).
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istration.1) No patients have previously been reported
to be aﬀected by oral intake9) and cytochrome
P450s.10) The pharmacokinetics and/or plasma dy-
namics are not diﬀerent between Japanese9) and non-
Japanese11) following a single oral administration
of usual dose (400mg) of GRNX and the time to
maximum concentrations (Tmax) were 2.46 hr and
the maximum plasma concentrations achieved
(Cmax) were 7.43 mg/ml with Japanese.9) The sinus
node dysfunction appeared quickly in the current
case, namely at 10 minutes after the initial drug
intake and then the symptoms lasted for about 21
hours. The serum concentrations of GRNX which
were taken 2 and 9 hours after the administration of
GRNX indicated that peak serum concentrations may
occur during this period. This eﬀect was thought to
be compatible with the drug concentration of GRNX.
The potential cardiotoxicity of quinolones has
been discussed and the administration of ﬂuoroqui-
nolones has been shown to speciﬁcally prolong the
QT interval, an event which may be associated with
the onset of Tdp and potentially life-threatening
ventricular arrhythmias.12) However, multiple oral
doses of GRNX are well tolerated and do not
demonstrate clinically signiﬁcant eﬀects on the QT
interval in Japanese3) and non-Japanese patients.11)
Other cardiac side eﬀects of GRNX are reported
in the web site of TAISYO TOYAMA Pharmaceut-
ical Co. Ltd., and bradycardia in 2 (0.3%) and sinus
arrhythmia in 1 (0.1%) out of 702 patients were
observed in a phase III study in Japan. A phase III
study with non-Japanese showing arrhythmia in 1
(<0:05%) and bradycardia in 1 (<0:05%) patient is
reported in the same web site. A Japanese case of
bradycardia induced by a single oral dose of GRNX
with a minimum heart rate was 14 beats/min was
reported in the same web site, thus suggesting the
presence of SSS, as in the current case. In that case,
however, the patient had had atrial ﬁbrillation and
the potassium level was elevated. The presence of
atrial ﬁbrillation might suggest that the patient
already had a potential for sinus node dysfunction
and the elevated potassium level could also inﬂuence
the sinus node function. Although the possibility of
sinus arrest is noted on the drug information for
GRNX, this caution is described only as a possible
side eﬀect as with other quinolone drugs, thus the
current case is the ﬁrst case of SSS in a patient who
was thought to have no other potential causes.
The QT prolongation results from inhibition of
potassium channels in heart muscle by quinolone.
The eﬀect of GRNX on potassium channels might be
nothing or milder than other quinolones because QT
prolongation is not clinically observed with this
drug. The ventricle threshold was normal in the
current case, but the other sites were unclear. The
acetylcholine-sensitive potassium channels might
have been involved in this case, because these
channels are only distributed in the atrial wall and
sinoatrial node and not in the ventricular wall. This
channel decreases the heart rate when acetylcholine
increases, usually due to the stimulation of para-
sympathetic nerves and GRNX might aﬀect this
channel and/or the parasympathetic nerve.
20hr
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Figure 3
ECG recorded after the insertion of a temporary pacemaker. The
time after the administration of GRNX is shown on the left side.
Only a ventricle wave with a pacemaker spike was observed until
19 hours after GRNX administration. Thereafter, the patient’s
native beats gradually increased and by 21 hours after admin-
istration, her sinus node function had completely improved.
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Nakamura13) demonstrated that drug-induced si-
nus dysfunction shows milder bradycardia, but a
signiﬁcantly lower blood pressure in comparison
with those with non-drug-induced SSS. Two out
of 42 patients in that study required a permanent
pacemaker because the sick sinus dysfunction did
not improve after the removal of the causative drug.
A decrease in the coronary artery blood ﬂow due
to low blood pressure might cause a transient
ischemic change in the sinus node and/or atrial
wall. However, this hypothesis was not applicable in
the current case because the patient felt palpitation
before faintness, thus suggesting that the low blood
pressure occurred after the sinus node dysfunction.
These ﬁndings strongly suggest that the sinus node
dysfunction in this patient was induced by GRNX.
Therefore, GRNX may produce sick sinus syndrome
in normal patients and this phenomenon should thus
be carefully considered whenever administering
GRNX.
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Table 1 Electrocardiographic time-dependent changes
1 year ago On Arrival 2nd day 3rd day 4th day
Time after administration (Medical Check) 2 hr 4 hr 8 hr 8.1 hr 12 hr 15 hr 20 hr 39 hr 63 hr
RR (sec) 1.089 1.057 0.880 1.765 4.550 1.180 1.190 1.000 0.938 0.984
PR (sec) 0.178 0.230 0.120 (*1) 0.180 0.165 0.180 0.180 0.200 0.190
QRS (sec) 0.103 0.105 0.115 0.090 0.100 0.050 0.060 0.068 0.100 0.100
QT (sec) 0.410 0.385 0.400 0.500 0.500 0.420 0.410 0.390 0.400 0.420
QTc 0.392 0.374 0.426 0.376 0.234 0.387 0.376 0.390 0.413 0.423
Pluse regular irregular ! ! (pacemaker) ! regular ! !
Drug Dopamine start ! ! off
Noradrenaline start ! ! ! off
*1 P wave was defect.
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